Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Cipralex (Escitalopram) – Germany: BGH reverses German Patent and Trademark Court decision on validity of Escitalopram patent and related SPC: Lundbeck v Neolab (Hoffmann Eitle) (The SPC Blog) (EPLAW Patent Blog) (IPKat)

Civil society, elected officials rally behind UNITAID patent pool (IP Watch) (IP Watch) (Managing IP)

Protection of intellectual property rights key to good clinical trials? (IP Whiteboard)

Civil society, elected officials rally behind UNITAID patent pool (IP Watch) (IP Watch) (Managing IP)

International policy network: Fake scare about fake drugs (IP Watch)

Counterfeit medicines at WHO: off board’s agenda, still on Secretariat’s (IP Watch)

Belgium: Appeal in descriptive seizure proceedings: Glaxo Smith Kline Biologicals v Novartis (EPLAW Patent Blog)

Brazil: Hypermarcas consolidates its position in Brazil’s generics markets (IP tango)

China: Prof. Potter about China’s Health Care Reform: ‘Do not forget cost of patent protection’ (IP Dragon)

US: Ariad’s reply brief: Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (Patent Docs)

US: Oral argument: Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (Patent Docs) (Patent Docs)

US: Does the Patent Act include a written description requirement separate from the enablement requirement?: Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (Inventive Step) (Patently-O)

US: Myriad amendments to Senate Health Care Reform Bill aimed at generic drugs (FDA Law Blog)

Alphagan (Brimonidine) – US: Exela appeals judgment that its ANDA for Brimonidine solution infringes several of Allergan’s patents (PATracer)

Angiomax (Bivalirudin) – US: The Medicines Company initiates 11th hour push for Angiomax Patent Term Extension; Petitions PTO to adopt a rule of construction for determining NDA approval date (FDA Law Blog)

Aricept (Donepezil) – US: Court denies discovery request by Teva to examine communications between Eisai and USPTO (Patent Docs) (GenericsWeb)

Cipralex (Escitalopram) – Germany: BGH reverses German Patent and Trademark Court decision on validity of Escitalopram patent and related SPC: Lundbeck v Neolab (Hoffmann Eitle) (The SPC Blog) (EPLAW Patent Blog) (IPKat)

Clobex (Clobetasol) – US: Patent infringement suit filing following Paragraph IV challenge: Galderma Laboratories, L.P. et al. v. Perrigo Co. et al. (Patent Docs)

Crestor (Rosuvastatin) –US: AstraZeneca fails to win summary judgment in Crestor patent battle against Apotex and others (GenericsWeb)

Cubicin (Daptomycin) – US: Trial date set Cubicin patent litigation against Teva (GenericsWeb)

Effexor (Venlafaxine) – US: Settlement announced in Effexor XR patent infringement dispute between Pfizer and Mylan (Patent Docs) (BioSpace)

Hexilate, Kogenate (Recombinant factor VIII) – US: Novartis Vaccines and Diagnostics and Novo Nordisk and Bayer and CSL Behring jointly ask court to stay patent infringement dispute, pending outcome of settlement negotiations (Patent Docs)

Lipitor (Atorvastatin) – US: Patent infringement suit filed following Paragraph IV challenge: Pfizer Inc. et al. v. Dr. Reddy’s Laboratories Ltd. et al. (Patent Docs)

Nuvigil (Armodafinil) – US: Cephalon files patent infringement suit against Actavis following Para IV challenge (Patent Docs) (GenericsWeb)

Thrombin(Coagulation factor II) – US: Court denies King Pharmaceuticals’ injunction motions against ZymoGenetics in trademark suit: King Pharmaceuticals, Inc. v. ZymoGenetics, Inc (Seattle Trademark Lawyer)

Viread (Tenofovir) – India: Gilead files Tenofovir appeal at IPAB (Spicy IP)